Young adult childhood cancer survivors have overall health-related quality of life similar to that of middle-aged adults. The presence or absence of chronic health conditions plays a crucial role in determining their sense of well-being, with those without conditions reporting higher scores.
A new study published in Cell Reports found that tumors with high neoantigen loads are more likely to be infiltrated by lymphocytes and have a better prognosis. Researchers hope this discovery will help identify patients most likely to benefit from immune checkpoint inhibitors, which have produced impressive results in some cases.
A public repository of patient-derived cancer models has been established to share this technique widely. The Public Repository of Xenografts (PRoXe) contains biopsy tissue collected from patients with leukemia and lymphoma, allowing researchers worldwide to access the portal and create PDX models for testing drugs.
A new blood test uses a liquid biopsy to detect genetic mutations in non-small cell lung tumors, providing a rapid and accurate method for identifying patients who can benefit from targeted therapies. The test was found to be highly accurate, with 100% predictive value for the primary EGFR mutation and 79% for the KRAS mutation.
A new study finds that CDK4/6 inhibitor abemaciclib can restore sensitivity to HER2-targeted treatments in breast cancer cells, overcoming drug resistance. The agent's effectiveness was confirmed in mouse models and paves the way for a clinical trial.
A high-fat diet drives a population boom of intestinal stem cells and generates a pool of 'stem-like' cells that can give rise to tumors. The study suggests a link between high-fat diets and increased colon cancer risk by altering the function of intestinal stem cells.
Researchers found that patients with lung and colorectal cancer who had financial distress at diagnosis reported significantly increased pain, symptom burden, and poorer quality of life. The study highlights the need for clinicians to target resources and treatments for patients struggling financially.
The ORFeome Collaboration has created a comprehensive library of open-reading frames, comprising 17,154 clones that code for full-length proteins. This resource allows researchers to express virtually any cell protein, enabling large-scale mapping of protein-protein interactions and functional screening.
Researchers at Dana-Farber Cancer Institute propose securitized consumer healthcare loans to spread the cost of therapies over many years, making them more accessible to patients. This approach aims to generate attractive returns to investors while providing affordable access to life-saving drugs and cures.
Researchers found that children with ALL who live in high-poverty areas are substantially more likely to experience early relapse, which is harder to treat. Despite receiving the same treatment, these patients have a higher risk of relapse within 36 months after first achieving complete remission.
The researchers discovered that genetic variations in IGHV1-69 gene affect the immune system's ability to recognize and fight influenza viruses, leading to variable vaccine effectiveness across ethnic groups. The findings may lead to new tools for predicting individual responses to vaccines and development of universal flu vaccines.
A recent study has found that most protein isoforms encoded by the same gene have radically different roles within tissues and cells, despite being structurally alike. This discovery suggests that each protein isoform needs to be studied individually to understand its normal role and potential involvement in disease.
A recent study identified the genetic mechanism causing angiocentric gliomas, a rare type of low-grade glioma in children. The discovery revealed an unusual DNA abnormality that triggers three different mechanisms to produce a tumor, leading to the development of a diagnostic test.
The iCat study successfully used clinical genomic sequencing to recommend therapy or diagnose changes in children with solid tumors. The findings support the use of personalized treatment based on tumor genetic characteristics, fueling potential drug development for pediatric and rare adult tumors.
A study by Dana-Farber Cancer Institute researchers found that factors such as hospice care duration, ICU admissions, and death location are associated with excellent end-of-life care. Expanding hospice access and revising Medicare provisions could improve quality of life for terminally ill patients.
Researchers discovered that lung cancer in younger patients has distinct genetic subtypes that can be treated with available targeted therapies. However, these patients' survival times are shorter than expected due to the more aggressive nature of the disease.
A pediatric study of 341 children with sickle cell disease found that prasugrel did not significantly reduce the rate of pain crises or severe lung complications. The trial, conducted across 13 developed and developing nations, was one of the largest and geographically broadest trials on sickle cell disease to date.
A pediatric chemotherapy regimen significantly improved outcomes for young adults with acute lymphoblastic leukemia (ALL), with a three-year overall survival rate of over 70%, according to Dana-Farber Cancer Institute scientists.
Researchers have identified four potential treatment opportunities for acute myeloid leukemia, including compounds targeting metabolism, internal communications, and protein transport. These findings represent significant progress in seeking out new ways to approach an intractable cancer.
Researchers at Dana-Farber Cancer Institute have conducted three studies demonstrating the effectiveness of new drug combinations in treating relapsed or treatment-resistant multiple myeloma. The trials showed impressive partial and complete remissions, as well as increased duration of remissions with tolerable side effects.
Midostaurin has been shown to improve the five-year survival rate of patients with high-risk acute myeloid leukemia (AML) who carry the FLT-3 gene mutation. The clinical trial found that midostaurin added to standard chemotherapy reduced the risk of death by 23% compared to placebo, resulting in a 50.9% five-year survival rate.
A clinical trial showed midostaurin, a multi-kinase inhibitor, improved the five-year survival rate of patients with high-risk acute myeloid leukemia (AML) who carry the FLT-3 gene mutation. The treatment resulted in a 50.9% survival rate compared to 43.9% for those without the mutation.
Researchers report improvements in four children treated with gene therapy for Wiskott-Aldrich syndrome, including reduced bleeding events and improved immunologic symptoms. The treatment's long-term safety and efficacy remain to be assessed as the children are monitored for 15 years.
Children with childhood leukemia benefit from prophylactic antibiotics, reducing serious bacterial infections during the first month of treatment by approximately 60 percent. The use of antibacterial prophylaxis appears to have made a profound difference for patients.
Researchers recommend hospitals create bereavement programs to support families through grief, preventing physical and mental health problems. The Dana-Farber Cancer Institute's program has shown positive effects, including a reduction in dysfunctional bereavement and its associated health issues.
A gene editing technique has been developed to increase the yield of laboratory-produced red blood cells, which could significantly reduce their cost. The technique targets a specific gene, SH2B3, and uses CRISPR gene editing to permanently shut it off in human embryonic stem cell lines.
A study published in Science reveals a mechanism that allows key immune system cells to restrain their more aggressive brother cells, protecting healthy tissue from assault. By targeting this genetic pathway with drugs, it may be possible to convert these cells into cancer-fighting cells.
Researchers analyzed genetic material from over 500 CLL patients, identifying dozens of genetic abnormalities linked to the disease. The study found that specific mutations affect treatment response and disease progression, providing insights into the complex interplay between different mutations in cancer cells.
Researchers identified a key mechanism driving prostate cancer development, where normal cells undergo epigenetic reprogramming to form malignant growth. The study provides insights into the origins of prostate cancer and potential targets for prevention and treatment.
A study published in JAMA Pediatrics reveals disparities in outcomes for children with retinoblastoma, a rare eye tumor, suggesting unequal access to primary care. Hispanic children and those from disadvantaged areas were more likely to lose an eye due to late diagnosis.
A new clinical trial has found that cabozantinib, a second-line therapy, controls the growth of advanced kidney cancer more effectively than everolimus. The results show improved progression-free survival and lower tumor growth rates, indicating potential for prolonged survival.
A recent study from Dana-Farber Cancer Institute found that nearly one-third of families with children undergoing cancer treatment experience food, housing, or energy insecurity. The research also revealed that many adults who support their families lose their jobs or take leaves due to their child's illness.
A randomized trial will recruit 3,000 women with Stage II and III breast cancer to receive either aspirin or a placebo. The study aims to determine if aspirin can prevent breast cancer recurrence and death, with potential benefits including enhanced survival and reduced costs in developing nations.
Researchers have identified a specific location in the enhancer that, when cut, leads to increased production of fetal hemoglobin. This breakthrough may pave the way for developing gene editing approaches for treating sickle cell disease and related hemoglobin disorders.
Daratumumab, a monoclonal antibody targeting CD38, showed significant promise against difficult-to-treat disease in patients with advanced multiple myeloma, achieving durable responses in 36% of patients, including complete remissions and very good partial responses.
A new study from Dana-Farber Cancer Institute found that regular coffee consumption, especially four or more cups a day, significantly reduces cancer recurrence and death in stage III colon cancer patients. The researchers discovered that caffeine is the key component responsible for this protective effect.
A new study from Dana-Farber Cancer Institute found that consuming four or more cups of coffee daily can lower the risk of colon cancer recurrence by 42% and mortality by 33%. The study's authors suggest that caffeine may increase insulin sensitivity, reducing inflammation and cancer risks.
Patients with metastatic prostate cancer who received a two-drug combination of chemotherapy and hormone blocker lived longer than those on hormone-blocker alone, surviving for 57.6 months versus 44 months. The treatment also delayed disease progression by six months.
Researchers developed a new compound that stops B-cell acute lymphoblastic leukemia by locking a disease-related protein in an inactive state. The compound showed promise in animal studies, with improved survival rates and reduced side effects when combined with steroids.
A recent study found that over two-thirds of adolescent and young adult cancer patients utilize aggressive interventions in the last month of life, including intensive care and chemotherapy. The researchers suggest a need for further research into supporting these patients to make informed end-of-life choices.
Scientists demonstrate how chromothripsis, a massive DNA rearrangement, occurs in single cancer cells. Chromothripsis is caused by a glitch in cell division that leads to the formation of micronuclei.
A recent study has identified genetic abnormalities in prostate cancer that can be targeted with existing or potential drugs, providing a new approach to treatment. The research found that nearly all tumors had at least one genetic aberration, including mutations in the androgen receptor gene.
Dana-Farber Cancer Institute scientists have developed a new, potent form of targeted cancer therapy using tumor cells' own protein-chopping machinery. The approach causes cancer cells to die quickly, potentially preventing resistance to conventional targeted therapies.
A drug developed in the late 1950s and abandoned due to toxicity has been revived as a treatment for advanced colorectal cancer. The drug, TAS-102, extended patients' overall survival and delayed disease progression with minimal side effects.
A novel blood test can rapidly predict the severity of radiation injury, enabling timely medical intervention and improving overall survival. The test uses microRNA biomarkers to determine the functional impact of radiation on bone marrow and other organs.
Men who took statin drugs while receiving androgen deprivation therapy for prostate cancer had a longer disease control period compared to those who didn't take statins. The study found that statins could delay disease progression by reducing the tumor's available androgen pool.
Researchers at Dana-Farber Cancer Institute identified three types of resistance to a new lung cancer drug, highlighting the need for combination therapies and novel strategies to overcome resistance mechanisms.
A new clinical trial results show that ibrutinib continues to control Waldenstrom's Macroglobulinemia, with a median overall response rate of 91% after 19 months of treatment. The disease shows sustained benefit in patients who survived for two years.
Researchers at Dana-Farber Cancer Institute have identified Eya1 as a critical protein in both normal brain development and the development of medulloblastoma. Lowering Eya1 levels in mice with medulloblastoma reduced death rates from the disease by half, suggesting it as a prime target for new treatments.
A new study from Dana-Farber Cancer Institute found that many websites marketing personalized cancer care services make exaggerated claims, with 88% offering nonstandard tests lacking clear clinical utility. The researchers urge consumers and healthcare providers to critically evaluate these services.